In the European Union,<unk>  is indicated for the treatment of COVID-19 in people aged twelve years of age and older and weighing at least who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
Sotrovimab
Atoltivimab
Odesivimab
Obiltoxaximab
Regdanvimab
Maftivimab
Nirsevimab
Bebtelovimab